By vgreene, 1 December, 2020 No significant difference in 28 day mortality possible lower mortality rate in pts 60 yo w methylprednisolone in subgroup analysis
By vgreene, 1 December, 2020 Randomized double blind controlled study 393 hospitalized pts mean age 55 57y w COVID 19 received methylprednisolone 0 5 mg kg IV bid x5 days n 194 or placebo n 199 81 3 pts w lab confirmed dz
By vgreene, 1 December, 2020 Study considerations randomized small sample size high overall mortality compared w other settings late methylprednisolone admin in some pts
By vgreene, 1 December, 2020 KEY FINDINGS short course methylprednisolone did not reduce mortality in hospitalized pts
By vgreene, 1 December, 2020 Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 COVID 19 Metcovid A Randomized Double blind Phase IIb Placebo controlled Trial
By vgreene, 30 November, 2020 sipuleucel T for pts w no or minimal sx no liver metastases life expectancy 6mo and an ECOG score of 0 1 17 Day 1 sipuleucel T dose 50 million autologous CD54 cells IV x1 Cycled q14 days x3 cycles
By vgreene, 30 November, 2020 radium Ra 223 dichloride for symptomatic bone metastases 15 Day 1 radium Ra 223 dichloride 55 kBq kg dose IV x1 Cycled q28 days x6 cycles
